神经营养因子酪氨酸激酶受体(NTRK)融合肿瘤的概念近年来出现。此外,NTRK融合在常见肿瘤中不常见,但通常可以在罕见肿瘤中发现。NTRK融合宫颈或子宫肿瘤由于其发病率极低,主要通过病例报告得到认可。在这项研究中,我们报道了1例新的EML4-NTRK3融合宫颈肉瘤,以增强其认识.据我们所知,这是中国机构的第一例。我们还进行了文献综述,其中NTRK融合宫颈肿瘤19例,子宫肿瘤4例。我们总结了临床病理特征,治疗方法,以及这些病例的预后。根据现有信息,我们观察到手术和完全切除,如果可能,仍然是主要的治疗模式。此外,越来越多的研究表明原肌球蛋白受体激酶(TRK)抑制剂能改善NTRK基因融合的癌症患者的预后,为转移性病变患者提供了一线希望。通过单变量生存分析,我们发现年龄和有丝分裂率可能与复发或转移有关。为了得出更有说服力的结论,有必要建立一个国际罕见病例数据库,并汇总这些零星病例。
The concept of neurotrophic factor tyrosine kinase receptor (NTRK) fusion tumor has emerged in recent years. Moreover, NTRK fusion is unusual in common tumors but can often be identified in rare tumors. The NTRK fusion cervical or uterine tumors are mainly recognized through case reports due to their extremely low incidence. In this study, we reported a new case of EML4-NTRK3 fusion cervical sarcoma to enhance its recognition. To the best of our knowledge, this is the first case from a Chinese institution. We also conducted a literature
review, in which a total of 19 cases of NTRK fusion cervical tumors and 4 cases of uterine tumors were retrieved. We summarized the clinicopathological features, treatment methods, and prognosis of these cases. Based on available information, we observed that surgery and complete excision, if possible, are still the primary modes of therapy. In addition, an increasing number of studies have shown that tropomyosin receptor kinases (TRK) inhibitors can improve the prognosis of cancer patients with NTRK gene fusion, which gives a silver lining for patients with metastatic lesions. We found that age and mitotic rate may be associated with recurrence or metastasis by univariate survival analysis. To draw more convincing conclusions, there is a need to establish an international database of rare cases and aggregate these sporadic cases.